top of page

She Tried all Cancer Treatment for Chordoma Bone Cancer and Finally Won Her Battle with ECCT


Cancer Treatment for Chordoma Bone Cancer

She Tried all Cancer Treatment for Chordoma Bone Cancer and Finally Won Her Battle with ECCT.

Cancer Treatment for Chordoma Bone Cancer

A 35-year-old woman who faced the challenges of a malignant chordoma diagnosis. Her journey began in February 2015 when she presented symptoms of shortness of breath and severe back pain. A CT scan revealed a mass in the T1-T3 vertebral corpuscles, causing destruction and exerting pressure on the esophagus and trachea. Subsequent biopsy results confirmed the presence of chordoma.


In March 2015, she underwent a single level anterior cervical discectomy and graft cage replacement. Following the surgery, a course of 25 days of radiotherapy (RT) was administered. Unfortunately, the post-RT MRI indicated that the condition had progressed. Determined to combat the disease, she embarked on a 3-year chemotherapy regimen, including 2 years of sunitinib, followed by 6 months of sorafenib, and another 6 months of imatinib. However, the tumor remained resilient.


In March 2021, a lesion resulting from a pathological fracture in her left femur confirmed the persistence of chordoma. By September 2021, her condition had worsened significantly, with a 6.5 cm mass lesion destroying the S1 vertebral body and left lateral elements. Additionally, a nodular lytic lesion of 1.5 cm appeared in the posterior of the left transverse process of the L5 vertebra. The existing lesions had also grown larger, measuring 7.5x5 cm.

In January 2022, a relapse was detected as a 13x9 mm mass in the middle part of her left femur. She began a regimen of cyclophosphamide and etoposide, but despite her efforts, the cancer continued its progression, affecting her femur and sacrum. Frustratingly, the mass sizes continued to increase despite her treatments.


A turning point arrived in February 2022 when Natalie decided to try ECCT. Remarkably, her mediastinal, sacral, and femoral lesions started to regress in size. Previously wheelchair-bound, she regained her ability to walk unassisted thanks to ECCT.

Cancer Treatment for Chordoma Bone Cancer

Notably, her pain levels decreased significantly, resulting in reduced dependence on pain medication.

Before ECCT, her condition was marked by persistent progression and treatment resistance. With the introduction of ECCT, both clinical and radiological responses became evident. The tumors began to shrink, and Natalie experienced a remarkable improvement in her quality of life, regaining mobility and independence that had once seemed lost.


她是一位35岁的女士,面对着恶性脊索瘤的诊断所带来的挑战。她的旅程始于2015年2月,当时她出现了呼吸急促和剧烈的背痛症状。CT扫描显示在T1-T3椎体中发现了一个肿块,该肿块破坏并压迫食道和气管。随后的活检结果确认了脊索瘤的存在。
在2015年3月,她接受了单节段前颈椎切除术和植骨笼置换术。手术后进行了为期25天的放疗(RT)。不幸的是,放疗后的MRI显示情况恶化。为了对抗疾病,她开始了为期3年的化疗方案,包括2年的舒尼替尼,随后是6个月的索拉非尼,以及另外6个月的依马替尼。然而,肿瘤仍然坚韧不拔。

在2021年3月,由于左股骨的病理性骨折,出现了一个病变,进一步证实了脊索瘤的存在。到了2021年9月,她的情况恶化得很严重,一个直径为6.5厘米的肿块破坏了S1椎体和左侧横突。此外,在L5椎体的左侧横突的后部出现了一个直径为1.5厘米的结节性溶骨病变。现有的病变也变得更大,尺寸为7.5x5厘米。

到了2022年1月,中部左股骨出现一个13x9毫米的肿块,意味着病情复发。她开始接受环磷酰胺和依托泊苷的治疗,但尽管付出了努力,癌症仍在持续发展,影响到她的股骨和骶骨。令人沮丧的是,肿块的大小在治疗后继续增加。

转折点出现在2022年2月,她开始接受电容癌症疗法(ECCT)。引人瞩目的是,她的纵隔、骶骨和股骨的病变开始缩小。此前,她需要坐轮椅,但在接受ECCT后,她恢复了独立行走的能力。值得注意的是,她的疼痛程度显著减轻,从而减少了对止痛药物的依赖。
在ECCT之前,她的病情持续恶化,对治疗产生抵抗。引入ECCT后,临床和放射学的反应都变得明显。肿瘤开始缩小,她的生活质量显著改善,她重新获得了移动性和独立性,这些曾经似乎已经失去。

Comments


bottom of page